Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects

NCT06161220 is registered in ClinicalTrials.gov with Impax Laboratories, LLC as lead sponsor.

NCT NCT06161220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06161220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects
Lead sponsor
Impax Laboratories, LLC
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2023
Completion date
December 5, 2023
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac repolarization in healthy subjects